Lilly partners with startup Fauna Bio to see if a squirrel’s hibernation could lead to new obesity drugs

Eli Lilly already has multiple obesity drug candidates in mid- and late-stage clinical development to pad its success with its GIP and GLP-1 drug …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lil­ly part­ners with start­up Fau­na Bio to see if a squir­rel’s hi­ber­na­tion could lead to new obe­si­ty drugs